RA Capital

Founded in Boston in 2004, RA Capital is an investment firm specializing in life sciences and drug development. Its team, with backgrounds in biology, chemistry, medicine, and industry experience, invests in early-stage companies with promising technologies and products across healthcare and life science sectors.

Anthony Arceci

Associate

Daniel Bahcheli

Associate

Peter Balogh

Analyst

Ryan Berry

Associate

Tess Cameron

Principal

Theresa Cameron

Principal, Strategic Finance

Ross Chikarmane

Associate

Maxwell DeNies

Senior Associate

Derek DiRocco

Partner

Cristina Ghenoiu

Principal

Cosmas Giallourakis

Venture Partner

Michael Gillespie

Senior Associate

Reza Halse

Partner

Matthew Hammond Ph.D

Principal

Jenna Hebert

Associate

Peyman Hosseinchi

Associate

Sonia Kartha

Associate

Peter Kolchinsky

Managing Partner

Anurag Kondapalli

Principal

Christy Tzu-yun Kuo

Senior Associate

Alyssa Larson

Associate

Andrew Levin

Managing Partner

Jon Lundt

Senior Associate

Dan Marks

Principal

Kathryn Meng

Investment Director

David Migl

Senior Associate

Emily Minkow

Venture Partner

Fuad Naser

Associate

Brigid O'Brien

Managing Partner

Josh Resnick

Senior Managing Director

Prithviraj Singha Roy

Analyst

Zachary Scheiner Ph.D

Principal

Zach Scheiner

Principal

Rajeev Shah

Managing Director

Rebecca Silberman

Associate

Jake Simson

Partner

Monica Stanciu

Associate

Katherine Terranova

Associate

Jack Vailas

Senior Associate

Shan Shan Wang

Associate

Past deals in South Dakota

SAb Biotherapeutics

Post in 2023
SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.